Protocol: Doxorubicin/Cisplatin - Mid-Western …

Department of Medical Oncology Chemotherapy Protocols 3rd Edition 78 Protocol: Doxorubicin/Cisplatin Indications: Osteosarcoma - neoadjuvant

  Protocol, Doxorubicin, Cisplatin, Doxorubicin cisplatin

Protocol: ABVD - Mid-Western Cancer Centre

Department of Medical Oncology Chemotherapy Protocols 3rd Edition 84 Protocol: ABVD Indications: Hodgkin’s disease Schedule:

  Indications, Abvd, Abvd indications

Protocol: Carboplatin/Gemcitabine

Department of Medical Oncology Chemotherapy Protocols 3rd Edition 2 Protocol: Cisplatin/Gemcitabine Indications: Lung Cancer (non-small cell) – Adjuvant, Neoadjuvant

  Protocol, Carboplatin, Gemcitabine, Carboplatin gemcitabine

Protocol: PCV (Procarbazine/CCNU/Vincristine)

Department of Medical Oncology Chemotherapy Protocols 3rd Edition 100 Protocol: PCV (Procarbazine/CCNU/Vincristine) Indication: Brain Tumours – Palliative

  Protocol, Tumours, Vincristine, Procarbazine ccnu vincristine, Procarbazine, Ccnu

Protocol: BEP 3-day (Bleomycin/Etoposide/Cisplatin)

Department of Medical Oncology Chemotherapy Protocols 3rd Edition 64 Protocol: Carboplatin Indications: Seminoma – stage 1 adjuvant

  Cisplatin, Bleomycin, Etoposide, 3 day, Bleomycin etoposide cisplatin, Seminoma

Department of Medical Oncology Chemotherapy …

Department of Medical Oncology Chemotherapy Protocols 3rd Edition 113 Mesna Dose Guidelines (RKG/OF/MK – December 05)

  Department, Medical, Protocol, Oncology, Chemotherapy, Department of medical oncology chemotherapy, Department of medical oncology chemotherapy protocols

Protocol: CF (Cisplatin/5-Fluorouracil)

Department of Medical Oncology Chemotherapy Protocols 3rd Edition 103 Protocol: CF (Cisplatin/5-Fluorouracil) Indications: Head and neck – metastatic, recurrent

  Protocol, Cisplatin, Fluorouracil, Cisplatin 5 fluorouracil

Protocol: Carboplatin/Paclitaxel - Mid-Western …

Department of Medical Oncology Chemotherapy Protocols 3rd Edition 57 Protocol: Carboplatin Indications: Ovarian Cancer – Advanced, Recurrent

  Protocol, Indications, Carboplatin, Paclitaxel, Carboplatin paclitaxel

AC (DOXOrubicin/Cyclophosphamide) Every 21 Days Course

CHEMOTHERAPY REGIMEN. 21-day cycle for 4 cycles • DOXOrubicin 60 mg/m2 IV Push on Day 1 • Cyclophosphamide 600 mg/m2 IV over 30 minutes on Day 1 • Oral hydration is strongly encouraged with cyclophosphamide; poorly hydrated patients may need supplemental IV hydration.

  Every, Doxorubicin, Days, Cyclophosphamide, Doxorubicin cyclophosphamide, Every 21 days

BCCA Protocol Summary for Adjuvant Therapy for Breast ...

5 mcg/kg/day Days 3 to 10 (or adjust as needed**) SC • Repeat cycle every 14 days x 4 cycles **reduce filgrastim treatment duration if ANC greater than 10 or intolerable bone

  Every, Days

BREAST CANCER TREATMENT REGIMENS (Part 1 of 6)

BREAST CANCER TREATMENT REGIMENS (Part 3 of 6) REGIMEN DOSING Recurrent or Metastatic Breast Cancer—Combination Therapy (continued) AT (doxorubicin + paclitaxel)1,20 Day 1: Doxorubicin 60mg/m 2 IV + paclitaxel 125–200mg/m 2 IV. Repeat cycle every 3 weeks.

  Treatment, Part, Every, Breast, Cancer, Doxorubicin, Regimens, Breast cancer treatment regimens

BCCA Protocol Summary for Adjuvant Therapy for Breast ...

(use non-DEHP bag and non-DEHP tubing with 0.22 micron or smaller in-line filter) Repeat cycle every 21 days x 4 cycles . DOSE MODIFICATIONS: 1. Hematological (for Day 1 counts)

  Every, Days, Every 21 days

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

One vial contains 150 mg of trastuzumab, a humanised IgG1 monoclonal antibody produced by mammalian (Chinese hamster ovary) cell suspension culture and purified by affinity and ion exchange